Urolithin A Supplementation to Improve Endothelial and Cerebrovascular Function in Middle-aged Adults With Obesity

Status: Completed
Location: See location...
Intervention Type: Dietary supplement, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is: \- Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity? Participants will be asked to: * Take the dietary supplement daily for 4 weeks * Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood Researchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 64
Healthy Volunteers: f
View:

• Age: 40-64 years old, inclusive

• Obesity \[BMI ≥30 kg/m2\]

• Ability to read, write, and speak English

• Competence to provide written informed consent

Locations
United States
Oklahoma
Translational GeroScience Laboratory - O'Donoghue Research Building
Oklahoma City
Time Frame
Start Date: 2023-10-02
Completion Date: 2025-05-14
Participants
Target number of participants: 50
Treatments
Experimental: Intervention
Placebo_comparator: Control
Sponsors
Leads: University of Oklahoma

This content was sourced from clinicaltrials.gov